德国孕妇疫苗开发与部署的机遇与挑战
孕妇免疫接种是保护孕妇和儿童的有力工具,但德国尚未对新型孕妇RSV疫苗作出官方推荐。本文审视德国孕妇接种疫苗在法律、监管、机构和社会文化层面的障碍,并提出改进可及性与接种率的可操作建议。
要点
- 德国尚未对孕妇RSV疫苗作出官方推荐。
- 孕妇接种可及性受法律、监管、机构和社会文化因素共同影响。
- 建议包括协调国家监管机构减少延迟、开展认知与素养宣传活动、加强疫苗临床研究能力建设。
核心结论
- 孕妇免疫接种是保护孕妇和儿童的有力工具,但德国在孕妇疫苗推荐和部署方面存在多重障碍,需采取可操作建议改善可及性与接种率。
研究设计与样本
- 本文为综述,审视德国孕妇疫苗接种的障碍并提出建议。
主要发现
- 德国尚未对孕妇RSV疫苗作出官方推荐。
- 德国孕妇接种可及性受法律、监管、机构和社会文化因素相互作用影响,包括临床研究环境较不宽松、推荐和推广延迟、医护人员和人群接受度较低。
临床怎么用
- 作者建议与其他国家监管机构协调以减少延迟、面向医护人员和公众开展认知与素养宣传活动、加强疫苗临床研究能力建设。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Maternal immunisation is a powerful tool to protect both pregnant women and their children. A new maternal RSV vaccine holds promise to protect newborns from RSV-associated illness in the first few months of life, but no official recommendation has been made in Germany. Since RSV causes a significant burden of paediatric hospital admissions, we consider it a pertinent opportunity to review barriers to maternal vaccination in Germany, which might also apply to other settings. Access to vaccination for pregnant women in Germany is shaped by an interplay of legal, regulatory, institutional, and sociocultural factors, with a less permissive clinical research environment, delays in recommendation and roll-out, and lower acceptance by healthcare professionals and the population. Actionable recommendations to improve availability and uptake include coordination with other national regulatory bodies to reduce delays, awareness and literacy campaigns for health professionals and the general public, and capacity building for vaccine clinical research.
引用
- Pley C, Kampmann B. Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany. Vaccine. 2024. PMID: 38944576. doi:10.1016/j.vaccine.2024.06.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。